Race Oncology says non-clinical toxicology and safety studies of lead drug RC220 Bisantrene successfully completed RC220 ...

Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate ...

Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate that ...